BIO FOr CARE: biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variants—design and status

被引：0
|
作者：
M. Jansen
I. Christiaans
S. N. van der Crabben
M. Michels
R. Huurman
Y. M. Hoedemaekers
D. Dooijes
J. D. H. Jongbloed
L. G. Boven
R. H. Lekanne Deprez
A. A. M. Wilde
J. J. M. Jans
J. van der Velden
R. A. de Boer
J. P. van Tintelen
F. W. Asselbergs
A. F. Baas
机构：
[1] Utrecht University,Department of Genetics, University Medical Centre Utrecht
[2] University of Groningen,Department of Genetics, University Medical Centre Groningen
[3] University of Amsterdam,Department of Clinical Genetics, Amsterdam UMC
[4] Erasmus University Medical Centre,Department of Cardiology, Thoraxcenter
[5] Radboud University Medical Centre,Department of Clinical Genetics
[6] University of Amsterdam,Heart Centre, Clinical and Experimental Cardiology, Amsterdam UMC
[7] Vrije Universiteit Amsterdam,Department of Physiology, Amsterdam UMC
[8] Amsterdam Cardiovascular Sciences,Department of Cardiology, University Medical Centre Groningen
[9] University of Groningen,Department of Cardiology
[10] Netherlands Heart Institute,Institute of Cardiovascular Science, Faculty of Population Health Sciences
[11] University Medical Centre Utrecht,Health Data Research UK and Institute of Health Informatics
[12] University College London,undefined
[13] University College London,undefined
来源：
Netherlands Heart Journal | 2021年 / 29卷
关键词：
Hypertrophic cardiomyopathy; MYBPC3; Biomarkers; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：318 / 329
页数：11
相关论文
共 50 条
  • [1] BIO FOr CARE: biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variants-design and status
    Jansen, M.
    Christiaans, I.
    van der Crabben, S. N.
    Michels, M.
    Huurman, R.
    Hoedemaekers, Y. M.
    Dooijes, D.
    Jongbloed, J. D. H.
    Boven, L. G.
    Lekanne Deprez, R. H.
    Wilde, A. A. M.
    Jans, J. J. M.
    van der Velden, J.
    de Boer, R. A.
    van Tintelen, J. P.
    Asselbergs, F. W.
    Baas, A. F.
    [J]. NETHERLANDS HEART JOURNAL, 2021, 29 (06) : 318 - 329
  • [2] Untargeted metabolomics identifies potential hypertrophic cardiomyopathy biomarkers in carriers of MYBPC3 founder variants
    Jansen, M.
    Schuldt, M.
    Schmidt, A. F.
    Christiaans, I.
    Van der Crabben, S. N.
    Dooijes, D.
    Jongbloed, J. D. H.
    Deprez, R. H. Lekanne
    Wilde, A. A. M.
    Jans, J. J. M.
    Van der Velden, J.
    De Boer, R. A.
    Van Tintelen, J. P.
    Asselbergs, F. W.
    Baas, A. F.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 6 - 7
  • [3] Untargeted Metabolomics Identifies Potential Hypertrophic Cardiomyopathy Biomarkers in Carriers of MYBPC3 Founder Variants
    Jansen, Mark
    Schuldt, Maike
    van Driel, Beau O.
    Schmidt, Amand F.
    Christiaans, Imke
    van der Crabben, Saskia N.
    Hoedemaekers, Yvonne M.
    Dooijes, Dennis
    Jongbloed, Jan D. H.
    Boven, Ludolf G.
    Deprez, Ronald H. Lekanne
    Wilde, Arthur A. M.
    Jans, Judith J. M.
    van der Velden, Jolanda
    de Boer, Rudolf A.
    van Tintelen, J. Peter
    Asselbergs, Folkert W.
    Baas, Annette F.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (04)
  • [4] Hypertrophic cardiomyopathy in Iceland: MYBPC3 founder mutation?
    Adalsteinsdottir, B.
    Teekakirikul, P.
    Seidman, J. G.
    Seidman, C. E.
    Maron, B. J.
    Danielsen, R.
    Gunnarsson, G. T.
    [J]. EUROPEAN HEART JOURNAL, 2012, 33 : 859 - 859
  • [5] Hypertrophic Cardiomyopathy in Iceland: MYBPC3 Founder Mutation
    Adalsteinsdottir, B.
    Teekakirkul, P.
    Maron, B. J.
    Gudbjartsson, D. F.
    Holm, H.
    Danielsen, R.
    Seidman, J. G.
    Seidman, C. S.
    Gunnarsson, G. T.
    [J]. CARDIOLOGY, 2013, 125 : 11 - 11
  • [6] Haploinsufficiency of MYBPC3 in the Development of Hypertrophic Cardiomyopathy
    Barefield, David
    Kumar, Mohit
    Gorham, Joshua
    Seidman, Jonathan
    Seidman, Christine
    de Tombe, Pieter
    Sadayappan, Sakthivel
    [J]. CIRCULATION, 2014, 130
  • [7] Prognosis in dutch mybpc3 founder mutation carriers is defined by phenotype
    Van Velzen, H. G.
    Schinkel, A. F. L.
    Oldenburg, R. A.
    Van Slegtenhorst, M. A.
    Frohn-Mulder, I. M. E.
    Michels, M.
    [J]. EUROPEAN HEART JOURNAL, 2015, 36 : 178 - 179
  • [8] ] Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers
    Adalsteinsdottir, Berglind
    Burke, Michael
    Maron, Barry J.
    Danielsen, Ragnar
    Lopez, Begona
    Diez, Javier
    Jarolim, Petr
    Seidman, Jonathan
    Seidman, Christine E.
    Ho, Carolyn Y.
    Gunnarsson, Gunnar Th
    [J]. OPEN HEART, 2020, 7 (01):
  • [9] Identification of founder MYBPC3 gene mutations in hungarian patients with hypertrophic cardiomyopathy
    Tringer, A.
    Hategan, L.
    Csanyi, B.
    Borbas, J.
    Palinkas, E.
    Nagy, V.
    Hegedus, Z.
    Nagy, I.
    Forster, T.
    Sepp, R.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 55 - 55
  • [10] Description of a Cohort with a New Truncating MYBPC3 Variant for Hypertrophic Cardiomyopathy in Northern Spain
    Suarez, Natalia Fernandez
    Ubierna, Maria Teresa Viadero
    Basas, Jesus Garde
    de la Fuente, Maria Esther Onecha
    Lanza, Maria Teresa Amigo
    Gorria, Gonzalo Martin
    Perez, Adrian Rivas
    Guerrero, Luis Ruiz
    Gonzalez-Lamuno, Domingo
    [J]. GENES, 2023, 14 (04)
12345